Some insurance plans require step therapy (trying one medication before another), and some providers prefer starting with less potent options
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
At four weeks, semaglutide participants had an average difference in body weight of 1.1% lower than those in the placebo group
It has a direct effect on both efforts to gain muscle and lose fat
Importantly, melanoma can present as diffuse patchy pigmentation
GLP-1 Longevity of Use The timeline of GLP-1 usage is distinctly different based on the drugs use case